MEDPAC REPORT FINDS NO SIGNIFICANT LINK BETWEEN 340B AND HIGHER CANCER DRUG SPENDING
WASHINGTON, D.C.— The following statement on the annual March report released today by the Medicare Payment Advisory Commission (MedPAC) is attributed to 340B President and CEO Maureen Testoni:
“The MedPAC report released today uses rigorous analysis and finds little evidence 340B participation influences cancer drug spending. Modest differences may be attributable to the types of patients treated in 340B facilities. The safety-net hospitals that participate in the 340B drug pricing program are essential providers of cancer care in this nation, especially to patients who are living with low incomes, those living with disabilities, and patients requiring more complex oncology care.”
Contact: Richard Sorian at email@example.com or 202-536-2285.